Peptides for anxiety disorders

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides for Anxiety Disorders Generalized anxiety disorder (GAD) affects approximately 3.1% of the U.S. adult population annually, often presenting with persistent worry, restlessness, and difficulty concentrating [1].

Peptides for Anxiety Disorders

Generalized anxiety disorder (GAD) affects approximately 3.1% of the U.S. adult population annually, often presenting with persistent worry, restlessness, and difficulty concentrating [1]. While benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) are common treatments, their side effect profiles, including sedation, dependence, and delayed efficacy, necessitate alternative strategies. Neuropeptides offer a promising therapeutic avenue by modulating neural circuits involved in fear and anxiety.

The brain’s intricate network of neuropeptides plays a crucial role in regulating emotional states. Neuropeptide Y (NPY), a 36-amino-acid peptide, acts as an endogenous anxiolytic, helping to dampen stress responses and promote resilience to trauma [2]. Individuals with lower NPY levels often exhibit increased vulnerability to anxiety and stress-related disorders. Modulating NPY activity, either directly or indirectly, represents a key target for anxiety intervention.

Selank, a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin, has demonstrated significant anxiolytic and neuroprotective effects. Clinical studies, primarily conducted in Russia, indicate that Selank can reduce anxiety symptoms comparable to benzodiazepines but without the associated sedative effects or risk of dependence [3]. For instance, a 2008 clinical trial involving 30 patients with GAD found Selank to be as effective as a benzodiazepine in reducing anxiety, with the added benefit of improving cognitive function [4]. Selank is typically administered intranasally at doses ranging from 0.5 mg to 3 mg daily, often in cycles of 10-14 days. You'll find its mechanism involves modulating the activity of GABAergic and serotonergic systems, as well as influencing the expression of genes related to brain plasticity and stress response [5].

Semax, another synthetic heptapeptide derived from ACTH, is recognized for its nootropic and anxiolytic properties. It enhances brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) activity, crucial for neuronal health and resilience [6]. Semax has been shown to reduce anxiety-like behaviors and improve learning abilities in animal models of stress [7]. In clinical settings, Semax is often used to alleviate anxiety, particularly in individuals experiencing asthenic and anxiety-depressive disorders. It is typically administered intranasally at doses of 0.5 mg to 3 mg daily, for 5-14 days, offering a rapid onset of action that can be beneficial for acute anxiety episodes.

While BPC-157 is primarily known for its regenerative properties, emerging research suggests its potential role in modulating central nervous system function, including anxiety. Animal studies indicate that BPC-157 can influence dopaminergic and serotonergic systems, which are implicated in mood and anxiety regulation [8]. Its ability to stabilize the gut-brain axis and reduce inflammation may indirectly contribute to anxiolytic effects, given the strong connection between gut health and mental well-being. Although direct clinical evidence for BPC-157 as a primary anxiolytic is limited, its neuroprotective effects could support overall brain health in anxious individuals. Typical BPC-157 dosing for systemic effects ranges from 200-500 mcg daily, administered subcutaneously, for 2-4 week cycles.

The nuance in using peptides for anxiety disorders lies in their targeted mechanisms compared to broad-spectrum anxiolytics. Benzodiazepines, for example, enhance GABAergic transmission throughout the brain, leading to generalized sedation and potential for dependence. Peptides like Selank and Semax, however, appear to exert more nuanced effects on specific neural pathways, potentially offering anxiolysis without significant sedation or addiction risk. It's important to consider peptides as adjunctive therapies, especially for patients who experience intolerable side effects from conventional medications or require support for cognitive function alongside anxiety reduction. You'll observe that while benzodiazepines provide immediate symptomatic relief, peptides aim for a more restorative neurobiological effect.

For a patient presenting with chronic GAD unresponsive to SSRIs, consider a trial of intranasal Selank at 1 mg twice daily for 14 days, monitoring for reductions in generalized worry and improvements in concentration, as it offers a distinct mechanism of action compared to traditional anxiolytics.

References

[1] National Institute of Mental Health. (2023). Anxiety Disorders. Retrieved from https://www.nimh.nih.gov/health/statistics/anxiety-disorders

[2] Morgan, C. A., et al. (2000). Relationships of Plasma Neuropeptide Y Concentrations to Traumatic Stress Exposure and Posttraumatic Stress Disorder in Special Operations Forces Soldiers. Biological Psychiatry, 47(10), 902–909.

[3] Seredenin, S. B., et al. (2008). Selank: a novel anxiolytic peptide. Bulletin of Experimental Biology and Medicine, 146(1), 105-107.

[4] Seredenin, S. B., et al. (2008). Selank: a novel anxiolytic peptide. Bulletin of Experimental Biology and Medicine, 146(1), 105-107.

[5] Dolotov, O. V., et al. (2016). Semax and Selank: Peptides with a wide range of neurobiological activities. Journal of Peptide Science, 22(1), 1–10.

[6] Dolotov, O. V., et al. (2016). Semax and Selank: Peptides with a wide range of neurobiological activities. Journal of Peptide Science, 22(1), 1–10.

[7] Gusev, E. I., et al. (2010). Clinical efficacy of Semax in patients with asthenic and anxiety-depressive disorders. Neuroscience and Behavioral Physiology, 40(7), 711-716.

[8] Sikiric, P. C., et al. (2016). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Pharmaceutical Design, 22(12), 1612–1621.